Literature DB >> 19703828

Coagulation factors in the airways in moderate and severe asthma and the effect of inhaled steroids.

F J H Brims1, A J Chauhan, B Higgins, J K Shute.   

Abstract

BACKGROUND: There is evidence of activation of the extrinsic coagulation cascade in the asthmatic airway, and both plasma and locally derived factors may be involved. The hypothesis that the normal haemostatic balance of healthy airways sampled by sputum induction favours fibrin formation in asthmatic airways, and that inhaled corticosteroids (ICS) and plasma exudation influence this balance, was tested.
METHODS: ELISA and activity assays were used to measure alpha(2)-macroglobulin (an index of plasma leakage) and coagulation factors in hypertonic saline-induced sputum of 30 stable subjects (10 controls, 10 with moderate asthma and 10 with severe asthma). Additionally, the moderate cohort were weaned off their ICS, followed by further sputum induction 5 days after cessation of steroids.
RESULTS: ICS wean induced a significant rise in plasminogen (median (interquartile range (IQR)): 13.92 (6.12-16.17) vs 4.82 (2.14-13.32) ng/ml; 95% CI 0.003 to 8.596, p = 0.0499) and tissue plasminogen activator (tPA; 5.57 (3.57-14.35) vs 3.88 (1.74-4.05) ng/ml; 95% CI 0.828 to 9.972, p = 0.0261) levels in sputum, such that tPA in untreated moderate asthma was significantly (p = 0.0029) higher than normal (2.14 (0.0-2.53) ng/ml). Subjects with severe asthma had significantly more alpha(2)-macroglobulin (p = 0.0003), tissue factor (p = 0.023), plasminogen activator inhibitor (p = 0.0091), thrombin-activatable fibrinolysis inhibitor (p = 0.0031) and fibrin degradation products (p = 0.0293) in their sputum than control subjects.
CONCLUSION: Untreated moderate asthma is associated with increased fibrinolysis that is corrected by ICS. Severe asthma and high dose corticosteroid therapy is associated with a profibrinogenic, antifibrinolytic environment in the airways. This study suggests that inhibition of fibrin deposition in severe asthma may be a therapeutic approach.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19703828     DOI: 10.1136/thx.2009.114439

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  20 in total

1.  Increased thrombin-activatable fibrinolysis inhibitor levels in patients with chronic rhinosinusitis with nasal polyps.

Authors:  Yoshimasa Imoto; Atsushi Kato; Tetsuji Takabayashi; Whitney Stevens; James E Norton; Lydia A Suh; Roderick G Carter; Ava R Weibman; Kathryn E Hulse; Kathleen E Harris; Anju T Peters; Leslie C Grammer; Bruce K Tan; Kevin Welch; Stephanie Shintani-Smith; David B Conley; Robert C Kern; Shigeharu Fujieda; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2019-09-25       Impact factor: 10.793

Review 2.  Coagulopathies and inflammatory diseases: '…glimpse of a Snark'.

Authors:  Silvina Del Carmen; Sophie M Hapak; Sourav Ghosh; Carla V Rothlin
Journal:  Curr Opin Immunol       Date:  2018-09-27       Impact factor: 7.486

Review 3.  Airway fibrinogenolysis and the initiation of allergic inflammation.

Authors:  Valentine Ongeri Millien; Wen Lu; Garbo Mak; Xiaoyi Yuan; J Morgan Knight; Paul Porter; Farrah Kheradmand; David B Corry
Journal:  Ann Am Thorac Soc       Date:  2014-12

4.  IL-13 Augments Compressive Stress-Induced Tissue Factor Expression in Human Airway Epithelial Cells.

Authors:  Jennifer A Mitchel; Silvio Antoniak; Joo-Hyeon Lee; Sae-Hoon Kim; Maureen McGill; David I Kasahara; Scott H Randell; Elliot Israel; Stephanie A Shore; Nigel Mackman; Jin-Ah Park
Journal:  Am J Respir Cell Mol Biol       Date:  2016-04       Impact factor: 6.914

5.  Tissue Factor Facilitates Wound Healing in Human Airway Epithelial Cells.

Authors:  Michael D Davis; Isao Suzaki; Shuichi Kawano; Kosaku Komiya; Qing Cai; Youngman Oh; Bruce K Rubin
Journal:  Chest       Date:  2018-10-22       Impact factor: 9.410

6.  Excessive fibrin deposition in nasal polyps caused by fibrinolytic impairment through reduction of tissue plasminogen activator expression.

Authors:  Tetsuji Takabayashi; Atsushi Kato; Anju T Peters; Kathryn E Hulse; Lydia A Suh; Roderick Carter; James Norton; Leslie C Grammer; Seong H Cho; Bruce K Tan; Rakesh K Chandra; David B Conley; Robert C Kern; Shigeharu Fujieda; Robert P Schleimer
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

7.  Airway factor XIII associates with type 2 inflammation and airway obstruction in asthmatic patients.

Authors:  Stephane Esnault; Elizabeth A Kelly; Ronald L Sorkness; Michael D Evans; William W Busse; Nizar N Jarjour
Journal:  J Allergy Clin Immunol       Date:  2015-10-30       Impact factor: 10.793

8.  Tissue factor-bearing exosome secretion from human mechanically stimulated bronchial epithelial cells in vitro and in vivo.

Authors:  Jin-Ah Park; Asma S Sharif; Daniel J Tschumperlin; Laurie Lau; Rachel Limbrey; Peter Howarth; Jeffrey M Drazen
Journal:  J Allergy Clin Immunol       Date:  2012-07-22       Impact factor: 10.793

9.  Interactions between glucocorticoid treatment and cis-regulatory polymorphisms contribute to cellular response phenotypes.

Authors:  Joseph C Maranville; Francesca Luca; Allison L Richards; Xiaoquan Wen; David B Witonsky; Shaneen Baxter; Matthew Stephens; Anna Di Rienzo
Journal:  PLoS Genet       Date:  2011-07-07       Impact factor: 5.917

10.  Sputum mediator profiling and relationship to airway wall geometry imaging in severe asthma.

Authors:  Dhananjay Desai; Sumit Gupta; Salman Siddiqui; Amisha Singapuri; William Monteiro; James Entwisle; Sudha Visvanathan; Harsukh Parmar; Radhika Kajekar; Christopher E Brightling
Journal:  Respir Res       Date:  2013-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.